EXAI News

Major advancements in artificial intelligence (AI) have attracted billions of dollars in new investment, and the IPO market has taken notice. The percentage of US IPOs referencing AI in their prospectuses has climbed in each of the past six years, and leapt to 54% in the year-to-date period. These references range from explanations of how a company uses AI, its plans to adopt the...read more

The IPO market remained active this past week as four IPOs raised $2.3 billion, joined by two direct listings. SPAC activity kept steady with nine blank check IPOs. New filers continue to pour into the IPO pipeline, with 17 IPOs and 10 SPACs submitting initial filings. NYSE direct listing Warby Parker (WRBY) opened for trading at $54 (+35% vs. reference price)...read more

Exscientia, which develops and licenses therapies designed with its AI drug discovery platform, raised $305 million by offering 13.9 million ADSs at $22, the high end of the range of $20 to $22. The company offered 0.8 million more ADSs than anticipated. It also raised an additional $160 million in concurrent private placements to SoftBank and the Gates Foundation. Exscientia...read more

Exscientia, which provides an AI-driven platform for drug design, discovery, and development, announced terms for its IPO on Monday. The Oxford, United Kingdom-based company plans to raise $275 million by offering 13.1 million ADSs at a price range of $20 to $22. The company plans to raise an additional $160 million in concurrent private placements to SoftBank and the Gates...read more